Characterization of two novel neuropeptides

描述（由申请人提供）：脑功能由神经递质和神经肽与其特异性受体的相互作用调节。这些相互作用的功能障碍是许多神经和精神疾病的原因。今天，已经确定了100多种不同的神经递质和神经肽。然而，基因组序列分析表明，大约50%的介导大脑功能的分子仍然是未知的。发现和表征这些分子将大大扩展我们对大脑功能的理解。我们开发了一种策略，称为孤儿受体策略，它使我们能够发现新的神经递质和神经肽。该策略使用孤儿G蛋白偶联受体（GPCR）作为“诱饵”来分离其天然配体。我们分析了两个孤儿GPCR，并确定了神经肽是他们的天然配体：黑色素浓集激素（MCH）和尾加压素II（UII）。我们从解剖学、解剖学和生物学的角度研究了这些系统。我们已经分离出一种MCH受体拮抗剂，并发现它能抑制食物摄入的享乐方面，我们现在建议分析这种拮抗剂对奖励反应的影响。我们还研究了两个最近发现的顺序相似的神经肽，NPB和NPW，结合孤儿GPCR，GPR 7。由于对这种新型神经肽系统的功能知之甚少，我们建议通过首先研究NPB在CNS中的作用位点来帮助确定其中心作用。我们已经获得了初步的解剖学和行为学数据，表明NPB可能作为一种抗焦虑剂。因为焦虑是对压力的反应，这可能会使NPB/NPW系统成为一个重要的医疗目标。我们建议通过分析NPB在不同焦虑相关实验中的作用来进一步研究这一作用。我们还建议将这些研究扩展到缺乏GPR 7受体的小鼠，并分析其先天焦虑水平。最后，我们建议通过应用我们用于鉴定MCH拮抗剂的方法来分离GPR 7拮抗剂，并使用这些拮抗剂进一步了解NPB/NPW系统在焦虑和可能的其他行为中的功能。

DESCRIPTION (provided by applicant): Brain functions are regulated by the interactions of neurotransmitters and neuropeptides with their specific receptors. Dysfunction in these interactions is the cause of many neurological and psychiatric disorders. Today, over 100 different neurotransmitters and neuropeptides have been identified. However, genomic sequence analyses show that about 50% of the molecules that mediate brain functions are still unknown. Finding and characterizing these molecules should significantly extend our understanding of brain function. We have developed a strategy, called the orphan receptor strategy, which allows us to discover novel neurotransmitters and neuropeptides. This strategy uses orphan G protein-coupled receptors (GPCRs) as "bait" to isolate their natural ligands. We analyzed two orphan GPCRs and identified the neuropeptides that are their natural ligands: melanin-concentrating hormone (MCH) and urotensin II (UII). We have studied these systems anatomically, pharmacologically and biologically. We have isolated a MCH receptor antagonist and have found that it can inhibit the hedonic aspect of food intake, e now propose to analyze the effects of this antagonist on rewarding responses. We have also studied two recently found equentially-similar neuropeptides, NPB and NPW, that bind to the orphan GPCR, GPR7. Since little is known about the function of this novel neuropeptide system, we propose to help identify its central roles by first study NPB sites of action in the CNS. We have already obtained preliminary anatomical and behavioral data that show that NPB may act as an anxiolytic agent. Because anxiety is a response to stress, this could set the NPB/NPW system as an important medical target. We propose to further study this role by analyzing NPB effect in different anxiety-related assays. We also propose to extend these studies to mice devoid of GPR7 receptor and analyze their innate level of anxiety. Finally we propose to isolate GPR7 antagonists, by applying the methodology that we used to identify MCH antagonists, and use these antagonists to further understand the function of the NPB/NPW system in anxiety and possibly other behaviors.